CSPC Pharmaceutical Group revenue and financials
$9.86Change from previous close: −1.40%Absolute change: −$0.14
In the fiscal year ended December 2025, CSPC Pharmaceutical Group reported revenue of ¥26.01B (−10.35% year over year). Net income was ¥3.88B, a net margin of 14.9%.
Fiscal year ending in December. Sources and method on the page Methodology and sources.
At a glance
- Revenue growth
- −10.35%
- 2025 vs 2024
- Net income growth
- −10.30%
- 2025 vs 2024
- Net margin
- 14.9%
- 2024: 14.9%
Financial data
Amounts in millions of CNY; per-share values in CNY; shares in millions.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | 5,832 | 4,535 | 4,179 | 7,627 | — |
| Depreciation and amortization | 1,413 | 1,339 | 1,117 | 1,048 | — |
| Capital expenditure | -2,280 | -2,679 | -1,893 | -2,723 | — |
| Investing cash flow | -3,878 | -3,858 | 866 | -6,796 | — |
| Financing cash flow | -2,612 | -5,253 | -2,560 | -1,904 | — |
| Dividends paid | -2,497 | -3,234 | -2,726 | -2,097 | — |
| Share repurchases | -278 | -1,579 | -200 | -14.2 | — |
| Debt issued | 21.0 | 28.0 | 0.0 | 486 | — |
| Debt repaid | -28.0 | -9.0 | -27.8 | -496 | — |
| Effect of exchange rates | -4.8 | 3.4 | 4.9 | 14.1 | — |
| Net change in cash | -658 | -4,577 | 2,485 | -1,073 | — |
| Free cash flow | 3,551 | 1,856 | 2,286 | 4,904 | — |